Clearside Biomedical (BST:CLM) - Hisse Senedi Fiyatı, Haberler ve Analizler

CLM Stoklara Genel Bakış

A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.

Şirket hakkında

CLM temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Gelirin yılda 65.68% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 3.5% oranında arttı

Risk Analizi

Hisse senetleri oldukça likit değildir

Negatif hissedar öz sermayesi

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( €98M )

+ 2 daha fazla risk

Clearside Biomedical, Inc. Rakipler

Apontis Pharma

XTRA:APPH

€80.5m

Pierrel

DB:2FJ0

€92.8m

Cantourage Group

XTRA:HIGH

€56.9m

Redx Pharma

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Clearside Biomedical
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.09
52 Haftanın En Yüksek Seviyesi	US$1.41
52 Haftanın En Düşük Seviyesi	US$0.81
Beta	2.35
11 Aylık Değişim	0%
3 Aylık Değişim	7.92%
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-80.88%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-89.17%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	CLM	DE Pharmaceuticals	DE Pazar
7D	0%	3.7%	1.0%
1Y	n/a	-7.6%	19.0%

Getiri vs. Endüstri: CLM un German Pharmaceuticals sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: CLM un German Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is CLM's price volatile compared to industry and market?
CLM volatility
CLM Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	8.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: CLM son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: CLM 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	30	George Lasezkay	clearsidebio.com

Clearside Biomedical, Inc. Temel Bilgiler Özeti

Clearside Biomedical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CLM temel i̇stati̇sti̇kler
Piyasa değeri	€87.71m
Kazançlar(TTM)	-€29.97m
Gelir(TTM)	€6.74m

13.0x

P/S Oranı

-2.9x

F/K Oranı

CLM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CLM gelir tablosu (TTM)
Gelir	US$7.52m
Gelir Maliyeti	US$142.00k
Brüt Kâr	US$7.38m
Diğer Giderler	US$40.84m
Kazançlar	-US$33.46m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.45
Brüt Marj	98.11%
Net Kâr Marjı	-444.66%
Borç/Özkaynak Oranı	-165.2%

CLM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CLM Stoklara Genel Bakış

Ödüller

Risk Analizi

Clearside Biomedical, Inc. Rakipler

XTRA:APPH

€80.5m

DB:2FJ0

€92.8m

XTRA:HIGH

€56.9m

DB:0RX

€65.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.15 loss in 1Q 2023)

Recent updates

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.15 loss in 1Q 2023)

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought €122k worth of stock

New minor risk - Market cap size

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 3Q 2022)

New major risk - Negative shareholders equity

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 1Q 2022)

High number of new directors

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

High number of new directors

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 1Q 2021)

High number of new directors

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

High number of new directors

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

High number of new and inexperienced directors

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020)

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.065 loss in 1Q 2020)

Clearside Biomedical, Inc. Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

Full year 2020 earnings released: US$0.39 loss per share (vs US$0.81 loss in FY 2019)

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (Axitinib Injectable Suspension) for the Treatment of Wet AMD